- Home
- QGEN vs EXEL Comparison
QGEN vs EXEL Comparison
Compare QGEN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QGEN | EXEL |
|---|---|---|
| Founded | 1986 | 1994 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 11.1B |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | QGEN | EXEL |
|---|---|---|
| Price | $55.53 | $44.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 23 |
| Target Price | ★ $48.84 | $45.45 |
| AVG Volume (30 Days) | ★ 2.4M | 2.3M |
| Earning Date | 02-04-2026 | 02-10-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ 331.25 | 53.55 |
| EPS | 1.94 | ★ 2.38 |
| Revenue | $2,070,781,000.00 | ★ $2,288,218,000.00 |
| Revenue This Year | $7.12 | $9.74 |
| Revenue Next Year | $5.95 | $12.27 |
| P/E Ratio | $28.76 | ★ $18.86 |
| Revenue Growth | 5.32 | ★ 9.93 |
| 52 Week Low | $39.61 | $31.90 |
| 52 Week High | $57.82 | $49.62 |
Technical Indicators
Market Signals| Indicator | QGEN | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 75.30 | 53.03 |
| Support Level | $46.07 | $43.00 |
| Resistance Level | $57.82 | $45.41 |
| Average True Range (ATR) | 1.91 | 1.57 |
| MACD | 0.93 | -0.08 |
| Stochastic Oscillator | 76.38 | 61.99 |
Price Performance
Historical ComparisonAbout QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.